Impact, healthcare utilization and costs of travel-associated mosquito-borne diseases in international travellers: a prospective study.


Journal

Journal of travel medicine
ISSN: 1708-8305
Titre abrégé: J Travel Med
Pays: England
ID NLM: 9434456

Informations de publication

Date de publication:
18 Nov 2023
Historique:
received: 06 02 2023
revised: 26 02 2023
accepted: 02 03 2023
medline: 21 11 2023
pubmed: 2 5 2023
entrez: 2 5 2023
Statut: ppublish

Résumé

International travellers frequently acquire infectious diseases whilst travelling, yet relatively little is known about the impact and economic burden of these illnesses on travellers. We conducted a prospective exploratory costing study on adult returning travellers with falciparum malaria, dengue, chikungunya or Zika virus. Patients were recruited in eight Travel and Tropical Medicine clinics between June 2016 and March 2020 upon travellers' first contact with the health system in their country of residence. The patients were presented with a structured 52-question self-administered questionnaire after full recovery to collect information on patients' healthcare utilization and out-of-pocket costs both in the destination and home country, and about income and other financial losses due to the illness. A total of 134 patients participated in the study (malaria, 66; dengue, 51; chikungunya, 8; Zika virus, 9; all fully recovered; median age 40; range 18-72 years). Prior to travelling, 42% of patients reported procuring medical evacuation insurance. Across the four illnesses, only 7% of patients were hospitalized abroad compared with 61% at home. Similarly, 15% sought ambulatory services whilst abroad compared with 61% at home. The average direct out-of-pocket hospitalization cost in the destination country (USD $2236; range: $108-$5160) was higher than the direct out-of-pocket ambulatory cost in the destination country (USD $327; range: $0-$1560), the direct out-of-pocket hospitalization cost at home (USD $35; range: $0-$120) and the direct out-of-pocket ambulatory costs at home (US$45; range: $0-$192). Respondents with dengue or malaria lost a median of USD $570 (Interquartile range [IQR] 240-1140) and USD $240 (IQR 0-600), respectively, due to their illness, whilst those with chikungunya and Zika virus lost a median of USD $2400 (IQR 1200-3600) and USD $1500 (IQR 510-2625), respectively. Travellers often incur significant costs due to travel-acquired diseases. Further research into the economic impact of these diseases on travellers should be conducted.

Sections du résumé

BACKGROUND BACKGROUND
International travellers frequently acquire infectious diseases whilst travelling, yet relatively little is known about the impact and economic burden of these illnesses on travellers. We conducted a prospective exploratory costing study on adult returning travellers with falciparum malaria, dengue, chikungunya or Zika virus.
METHODS METHODS
Patients were recruited in eight Travel and Tropical Medicine clinics between June 2016 and March 2020 upon travellers' first contact with the health system in their country of residence. The patients were presented with a structured 52-question self-administered questionnaire after full recovery to collect information on patients' healthcare utilization and out-of-pocket costs both in the destination and home country, and about income and other financial losses due to the illness.
RESULTS RESULTS
A total of 134 patients participated in the study (malaria, 66; dengue, 51; chikungunya, 8; Zika virus, 9; all fully recovered; median age 40; range 18-72 years). Prior to travelling, 42% of patients reported procuring medical evacuation insurance. Across the four illnesses, only 7% of patients were hospitalized abroad compared with 61% at home. Similarly, 15% sought ambulatory services whilst abroad compared with 61% at home. The average direct out-of-pocket hospitalization cost in the destination country (USD $2236; range: $108-$5160) was higher than the direct out-of-pocket ambulatory cost in the destination country (USD $327; range: $0-$1560), the direct out-of-pocket hospitalization cost at home (USD $35; range: $0-$120) and the direct out-of-pocket ambulatory costs at home (US$45; range: $0-$192). Respondents with dengue or malaria lost a median of USD $570 (Interquartile range [IQR] 240-1140) and USD $240 (IQR 0-600), respectively, due to their illness, whilst those with chikungunya and Zika virus lost a median of USD $2400 (IQR 1200-3600) and USD $1500 (IQR 510-2625), respectively.
CONCLUSION CONCLUSIONS
Travellers often incur significant costs due to travel-acquired diseases. Further research into the economic impact of these diseases on travellers should be conducted.

Identifiants

pubmed: 37129519
pii: 7147890
doi: 10.1093/jtm/taad060
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© International Society of Travel Medicine 2023. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Yesim Tozan (Y)

School of Global Public Health, New York University, New York, NY, United States.

Tyler Y Headley (TY)

New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.

Emilie Javelle (E)

Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées (IRBA), Marseille, France.
Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Philippe Gautret (P)

Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France.
IHU Méditerranée Infection, Marseille, France.

Martin Grobusch (M)

Center for Tropical and Travel Medicine, University of Amsterdam, Amsterdam, The Netherlands.

Cornelis de Pijper (C)

Center for Tropical and Travel Medicine, University of Amsterdam, Amsterdam, The Netherlands.

Hilmir Asgeirsson (H)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Unit of Infectious Diseases and Dermatology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.

Lin H Chen (LH)

Harvard Medical School, Boston, MA, United States.
Travel Medicine Center-Mt. Auburn Hospital, Cambridge, MA, United States.

Daniel L Bourque (DL)

Harvard Medical School, Boston, MA, United States.
Travel Medicine Center-Mt. Auburn Hospital, Cambridge, MA, United States.

Marta D Menéndez (MD)

Hospital Universitario La Paz-Carlos IIIl, IdiPaz, CIBERIfect, Madrid, Spain.

Lucia Moro (L)

Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.

Federico Gobbi (F)

Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.

Adrián Sánchez-Montalvá (A)

International Health Unit Vall d'Hebron-Drassanes, Infectious Diseases Department, Vall d'Hebron University Hospital, PROSICS, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Bradley A Connor (BA)

Weill Cornell Medicine and the New York Center for Travel and Tropical Medicine, New York, NY, United States.

Alberto Matteelli (A)

Clinic of Infectious and Tropical Diseases, University of Brescia and District Health Department, Brescia, Italy.
Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili of Brescia, Italy.

Verena Crosato (V)

Clinic of Infectious and Tropical Diseases, University of Brescia and District Health Department, Brescia, Italy.
Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili of Brescia, Italy.

Ralph Huits (R)

Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.

Michael Libman (M)

J.D. MacLean Centre for Tropical Diseases, Montreal, Quebec, Canada.

Davidson H Hamer (DH)

J.D. MacLean Centre for Tropical Diseases, Montreal, Quebec, Canada.
Boston University School of Public Health and Center for Emerging Infectious Diseases, Boston, MA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH